Spinal cord repair in MS

Objective: To investigate the mechanisms of spinal cord repair and their relative contribution to clinical recovery in patients with multiple sclerosis (MS) after a cervical cord relapse, using spinal cord 1H-magnetic resonance spectroscopy (MRS) and volumetric imaging. Methods: Fourteen patients with MS and 13 controls underwent spinal cord imaging at baseline and at 1, 3, and 6 months. N-acetyl-aspartate (NAA) concentration, which reflects axonal count and metabolism in mitochondria, and the cord cross-sectional area, which indicates axonal count, were measured in the affected cervical region. Mixed effect linear regression models investigated the temporal evolution of these measures and their association with clinical changes. Ordinal logistic regressions identified predictors of recovery. Results: Patients who recovered showed a sustained increase in NAA after 1 month. In the whole patient group, a greater increase of NAA after 1 month was associated with greater recovery. Patients showed a significant decline in cord area during follow-up, which did not correlate with clinical changes. A worse recovery was predicted by a longer disease duration at study entry. Conclusions: The partial recovery of N-acetyl-aspartate levels after the acute event, which is concurrent with a decline in cord cross-sectional area, may be driven by increased axonal mitochondrial metabolism. This possible repair mechanism is associated with clinical recovery, and is less efficient in patients with longer disease duration. These insights into the mechanisms of spinal cord repair highlight the need to extend spinal cord magnetic resonance spectroscopy to other spinal cord disorders, and explore therapies that enhance recovery by modulating mitochondrial activity.

[1]  David H. Miller,et al.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials , 2009, Nature Reviews Neurology.

[2]  P. Hanson,et al.  Edinburgh Research Explorer Mitochondrial Changes within Axons in Multiple Sclerosis Mitochondrial Changes within Axons in Multiple Sclerosis , 2022 .

[3]  D. Turnbull,et al.  Review: Mitochondria and disease progression in multiple sclerosis , 2008, Neuropathology and applied neurobiology.

[4]  Rohit Bakshi,et al.  MRI in multiple sclerosis: current status and future prospects , 2008, The Lancet Neurology.

[5]  Eliza M. Gordon-Lipkin,et al.  Optical coherence tomography and disease subtype in multiple sclerosis , 2007, Neurology.

[6]  P. Matthews,et al.  Axonal damage in the spinal cord of multiple sclerosis patients detected by magnetic resonance spectroscopy , 2007, Magnetic resonance in medicine.

[7]  O. Ciccarelli,et al.  Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. , 2007, Brain : a journal of neurology.

[8]  Timothy Edward John Behrens,et al.  Discordant white matter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis , 2007, NeuroImage.

[9]  J. Moffett,et al.  N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology , 2007, Progress in Neurobiology.

[10]  D. Turnbull,et al.  Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse , 2006, Journal of neuroscience research.

[11]  Jiani Hu,et al.  Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis , 2005, Multiple sclerosis.

[12]  Stephen J. Jones,et al.  Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis , 2005, Annals of neurology.

[13]  M. Rovaris,et al.  Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. , 2005, Archives of neurology.

[14]  Stephen J. Jones,et al.  A serial MRI study following optic nerve mean area in acute optic neuritis. , 2004, Brain : a journal of neurology.

[15]  F. Barkhof,et al.  The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. , 2004, Radiology.

[16]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[17]  Massimo Filippi,et al.  Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. , 2002, Archives of neurology.

[18]  Zografos Caramanos,et al.  Axonal metabolic recovery in multiple sclerosis patients treated with interferon β–1b , 2001, Journal of Neurology.

[19]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[20]  R. Rudick,et al.  Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.

[21]  W Steinbrich,et al.  Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. , 2000, AJNR. American journal of neuroradiology.

[22]  A. Thompson,et al.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.

[23]  Peter M. G. Munro,et al.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. , 1996, Neuroreport.

[24]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[25]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[26]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[27]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[28]  P. Matthews.  Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. , 2001, Journal of neurology.